On Jan. 26, 2022, Moderna announced that the first participant had been dosed in the Phase 2 study of the Company’s Omicron-specific booster candidate (mRNA-1273.529).>/p>

Additionally, Moderna announced the publication of neutralizing antibody data against the Omicron variant six months following a booster dose in The New England Journal of Medicine.